Evidence map›Paper›PMID 34548309›Full record

ArticleCancer discovery2022

Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant,

Pasi A Jänne, Christina Baik, Wu-Chou Su, Melissa L Johnson, Hidetoshi Hayashi, Makoto Nishio, Dong-Wan Kim, Marianna Koczywas, Kathryn A Gold, Conor E Steuer and 11 more

Erratum issuedOpen access · hybridAbstract readClinical Trial, Phase IMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer discovery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 195 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
195citing papers in PubMed, 9 pooled it
19.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

195 citing papers in PubMed, 9 syntheses or guidelines pooled it, 276 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. [Clinical Progress and Prospects of Antibody-drug Conjugates in Advanced NSCLC].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025
    Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Review
  16. Review
  17. Article
  18. Efficacy and safety of third-generationTranslational lung cancer research · 2026
    Article
  19. Review
  20. Review

135 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 15 institutions in 4 countries.

Pasi A JänneDana-Farber Cancer Institute, Boston, Massachusetts. Pasi_Janne@dfci.harvard.edu.ORCID 0000-0002-7821-4928
Christina BaikSeattle Cancer Care Alliance, Seattle, Washington.
Wu-Chou SuNational Cheng Kung University Hospital, Tainan, Taiwan.
Melissa L JohnsonSarah Cannon Research Institute/Tennessee Oncology, PLCC, Nashville, Tennessee.
Hidetoshi HayashiKindai University Hospital, Osaka-Sayama City, Japan.ORCID 0000-0001-8787-5587
Makoto NishioThe Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto-ku, Japan.ORCID 0000-0003-4969-4165
Dong-Wan KimSeoul National University College of Medicine and Seoul National University Hospital, Seoul, South Korea.ORCID 0000-0001-5124-7132
Marianna KoczywasCity of Hope Medical Center, Duarte, California.
Kathryn A GoldUniversity of California, San Diego, San Diego, California.ORCID 0000-0001-5165-4424
Conor E SteuerWinship Cancer Institute of Emory University, Atlanta, Georgia.
Haruyasu MurakamiShizuoka Cancer Center, Sunto-gun, Japan.ORCID 0000-0003-2416-546X
James Chih-Hsin YangNational Taiwan University Cancer Center, Taipei, Taiwan.
Sang-We KimAsan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.ORCID 0000-0003-1065-8095
Michele VigliottiDaiichi Sankyo, Inc., Basking Ridge, New Jersey.
Rong ShiDaiichi Sankyo, Inc., Basking Ridge, New Jersey.
Zhenhao QiDaiichi Sankyo, Inc., Basking Ridge, New Jersey.
Yang QiuDaiichi Sankyo, Inc., Basking Ridge, New Jersey.
Lihui ZhaoDaiichi Sankyo, Inc., Basking Ridge, New Jersey.
David SternbergDaiichi Sankyo, Inc., Basking Ridge, New Jersey.
Channing YuDaiichi Sankyo, Inc., Basking Ridge, New Jersey.ORCID 0000-0002-3231-2565
Helena A YuMemorial Sloan Kettering Cancer Center, New York, New York.
Daiichi Sankyo (United States) · USCity Of Hope National Medical Center · USDana-Farber Cancer Institute · USEmory University · USJapanese Foundation For Cancer Research · JPKettering University · USKindai University Hospital · JPNational Cheng Kung University Hospital · TWNational Taiwan University · TWSeattle Cancer Care Alliance · USSeoul National University Hospital · KRShizuoka Cancer Center · JPTennessee Oncology · USUniversity of San Diego · USUniversity of Ulsan · KR

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Receptor tyrosine-protein kinase ERBB3 (HER3) is expressed in most

Indexed as

AgedAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalCamptothecinCarcinoma, Non-Small-Cell LungDisease-Free SurvivalDose-Response Relationship, DrugErbB ReceptorsFemaleHumansInfusions, IntravenousLung NeoplasmsMaleMiddle AgedNeoplasm MetastasisTreatment OutcomeAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalCamptothecinEGFR protein, humanErbB Receptorspatritumab deruxtecan

Identifiers

PMID34548309
PMCPMC9401524
OpenAlexW3200329827

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.